FOSAPREPITANT DIMEGLUMINE Drug Patent Profile
✉ Email this page to a colleague
When do Fosaprepitant Dimeglumine patents expire, and when can generic versions of Fosaprepitant Dimeglumine launch?
Fosaprepitant Dimeglumine is a drug marketed by Accord Hlthcare, Apotex, Arthur Grp, Aspiro, Baxter Hlthcare Corp, Be Pharms, Chia Tai Tianqing, Dr Reddys, Eugia Pharma, Fresenius Kabi Usa, Geneyork Pharms, Lupin Ltd, MSN, Mylan Labs Ltd, Navinta Llc, Piramal Critical, Qilu Pharm Hainan, Sandoz, and Teva Pharms Usa. and is included in nineteen NDAs.
The generic ingredient in FOSAPREPITANT DIMEGLUMINE is fosaprepitant dimeglumine. There are eleven drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the fosaprepitant dimeglumine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Fosaprepitant Dimeglumine
A generic version of FOSAPREPITANT DIMEGLUMINE was approved as fosaprepitant dimeglumine by FRESENIUS KABI USA on June 9th, 2016.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for FOSAPREPITANT DIMEGLUMINE?
- What are the global sales for FOSAPREPITANT DIMEGLUMINE?
- What is Average Wholesale Price for FOSAPREPITANT DIMEGLUMINE?
Summary for FOSAPREPITANT DIMEGLUMINE
Recent Clinical Trials for FOSAPREPITANT DIMEGLUMINE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Fujian Shengdi Pharmaceutical Co., Ltd. | Phase 3 |
| Xijing Hospital | N/A |
| bahria international hospital | Phase 3 |
Pharmacology for FOSAPREPITANT DIMEGLUMINE
Anatomical Therapeutic Chemical (ATC) Classes for FOSAPREPITANT DIMEGLUMINE
Paragraph IV (Patent) Challenges for FOSAPREPITANT DIMEGLUMINE
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| EMEND | Injection | fosaprepitant dimeglumine | 150 mg/vial | 022023 | 2 | 2012-01-25 |
US Patents and Regulatory Information for FOSAPREPITANT DIMEGLUMINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accord Hlthcare | FOSAPREPITANT DIMEGLUMINE | fosaprepitant dimeglumine | POWDER;INTRAVENOUS | 204025-001 | Aug 26, 2020 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Qilu Pharm Hainan | FOSAPREPITANT DIMEGLUMINE | fosaprepitant dimeglumine | POWDER;INTRAVENOUS | 213106-001 | Sep 8, 2020 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Chia Tai Tianqing | FOSAPREPITANT DIMEGLUMINE | fosaprepitant dimeglumine | POWDER;INTRAVENOUS | 212143-001 | Mar 3, 2021 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
